NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; William Origer, MD, FAAFP; Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Patrick DeMartino, MD; Cat Livingston, MD, MPH; Tim Langford, PharmD, BCPS, USPHS; Robin Moody, MPH; Caryn Mickelson, PharmD.

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD, Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Dee Weston, JD; Brandon Wells; Amanda Parrish, LCSW.

Audience: Amber Mayzak, Pharmacyclics; Andrea Willcuts, Takeda; Becky Gonzales, ViiV Healthcare; BingBing Liang, CareOregon; **Boman Irani, Rhythm Pharmaceuticals**; Brad Brekke, Rhythm Pharmaceuticals; Brandie Ferger, Advanced Health CCO; Chi Kohlhoff, Viela Bio; Corrine Anway, OSU; **Dale Edberg, Horizon Therapeutics**; Dave Riepe, Merck; Dennis Schaffner, Sanofi Genzyme; Donald Nopper, Apellis Pharma; Erick Nash, Covis Pharma; Janeen McBride; **Jenny Todenhagen, Genentech**; Jeremy Strand, Alexion; Jim Graves, BMS; Kapeka Kast, PCYC; Katie Scheelar, EOCO/Moda Health; Keely Larson, Bayer; Laura Jeffcoat, Abbvie; Maggie Murphy, Teva Pharmaceuticals; Matt Worthy, OHSU, Matthew Wright, Artia Solutions; Timothy McFerron, Alkermes; Melissa Snider, Gilead; Michael Foster, BMS; Mike Nicholson; Paul Thompson, Alkermes; Pauline Whelan; **Raffaella Colzani, MD, Sanofi Genzyme**; **Shannon Zandy, Alexion Pharmaceuticals**; Tiffany Jones, PacificSource; Tracey Harrah, AVEO Oncology; Lori McDermott, Supernus; Norm Navarro, Providence; **Amy Yang, MD, OHSU**.

(*) Provided verbal testimony
Written testimony: Posted to OSU Website

I. CALL TO ORDER

A. The meeting was called to order at approximately 1:06 pm. Introductions were made by Committee members and staff
B. Conflict of Interest Declaration
C. Approval of February 2021 minutes presented by Mr. Citron
   ACTION: Motion to approve, 2nd, all in favor
D. Department and legislative updates provided by Dee Weston

II. CONSENT AGENDA TOPICS

A. Oncology Prior Authorization Update
   ACTION: Motion to approve, 2nd, all in favor

III. DUR NEW BUSINESS

A. Opioid Class Literature Scan: Andrew Gibler, PharmD
   Policy Evaluation: Sarah Servid, PharmD
   OHA Minimum Standard: Dee Weston
   Recommendations:
   - Update current policy with newly approved drug products
   - Modify high-risk opioid RetroDUR program criteria to include patients who may be paying cash for chronic opioid prescriptions and patients with a diagnosis of substance abuse or history of overdose
   - Notify providers about risk mitigation strategies and opportunities to improve care
   ACTION: The Committee recommended adding an assessment for OUD in the renewal criteria for both short-acting and long-acting PA criteria
   Motion to approve, 2nd, all in favor, one abstained

B. Antipsychotics in Children Drug Effectiveness Review Project (DERP) Summary: Sara Fletcher, PharmD
   Mental Health Polypharmacy Drug Use Evaluation: Sarah Servid, PharmD
   Recommendations:
   - No PDL changes recommended based on the clinical evidence
   - Evaluate costs in executive session
- Review profiles of patients with the following high-risk categories to identify opportunities for therapy optimization or de-prescribing: long-term use multiple mental health drugs; patients with possible contraindications to therapy; and very young children

**ACTIONS:**
The Committee requested staff bring back proposed safety-edit criteria to ensure appropriate use of antipsychotics for members less than five years old when initiating therapy with an antipsychotic and to require psychiatric/specialty consultation. The Committee also recommended identifying provider education opportunities to address off-label use of antipsychotics in kids and pursue strategies to notify prescribers

**Motion to approve, 2nd, all in favor**

---

### IV. PREFERRED DRUG LIST NEW BUSINESS

**A. Imcivree™ (setmelanotide) Abbreviated Drug Review (ADR):** Sara Fletcher, PharmD  
**State Plan Overview of Excluded Drugs:** Dee Weston, JD  
**Recommendation:**
- Continue to designate setmelanotide as not covered per Oregon Medicaid State Plan  
**Public Comment:** Boman Irani, Rhythm Pharmaceuticals  
**ACTIONS:** Motion to approve, 2nd, all in favor

**B. Lumizyme® (alglucosidase alfa) New Drug Evaluation (NDE):** David Engen, PharmD  
**Recommendations:**
- Add alglucosidase alfa to the lysosomal storage disorders PDL class and designate as non-preferred  
- Implement proposed alglucosidase alfa PA criteria to ensure medically appropriate use  
**Public Comment:** Raffaella Colzani, MD, Sanofi Genzyme; Amy Yang, MD, OHSU  
**ACTIONS:** Motion to approve, 2nd, all in favor

**C. Statins: Class Update:** Megan Herink, PharmD  
**Recommendations:**
- Continue to maintain preferred low-, moderate- and high-intensity statins  
- Combine high-potency and low-medium potency PDL classes into one PDL statin class  
- Evaluate costs in executive session  
**ACTIONS:** Motion to approve, 2nd, all in favor

**D. Neuromyelitis Optica Spectrum Disorder (NMOSD) Class Review:**  
Deanna Moretz, PharmD  
**Recommendations:**
- Add the “Biologics for Rare Diseases” class to the PDL and include inebilizumab and satralizumab
V. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; William Origer, MD, FAAFP; Mark Helm, MD, MBA, FAAP; Russell Huffman, DNP, PMHNP; Patrick DeMartino, MD; Cat Livingston, MD, MPH; Caryn Mickelson, PharmD; Robin Moody, MPH

Staff Present: Jennifer Bowen, Admin; Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Megan Herink, PharmD; Richard Holsapple, RPh; Deanna Moretz, PharmD; Sarah Servid, PharmD; Dee Weston, JD; Brandon Wells; Amanda Parrish, LCSW

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. Second Generation Antipsychotics:
   Recommendation: No changes to the PDL are recommended

B. Biologics for Rare Diseases: NMOSD treatments and C5 Inhibitors:
   Recommendation: Make eculizumab non-preferred; Make ravulizumab, satralizumab, and inebilizumab preferred

C. Statins Class update:
   Recommendation: Make rosuvastatin tablets preferred
   ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN